Case Study

Zuellig Pharma (C): Taking the next leap

8 pages
December 2020
Reference: IMD-7-2242

Case (C) is set in July 2020 when John Graham took over as Zuellig Pharma’s new CEO and he needed to decide how to take the company forward. Prior to that, John Graham had effectively led the company’s Commercial Solutions business. However, as the new CEO he needed to manage the entire portfolio of new solutions businesses and investments in digital startups. Zuellig Pharma had successfully navigated the first six months of the COVID-19 pandemic. It had benefited from its earlier efforts to increase the robustness of its supply chain as well as the resilience and dedication of its employees. The COVID-19 crisis had accelerated the roll-out of its new e-commerce platform, which allowed for online ordering and cash collection. At the same time, the company had suffered financially because some costs had significantly increased. Zuellig Pharma faced an even more difficult environment with new stakeholders (like patient groups and Ministries of Health) playing a more important role. Given these challenges, its leadership needed to decide how to take the company forward and ensure that it continues to thrive in the future.

Learning Objective
  • Portfolio management of new businesses: exploration, viability and scaling up.
  • Risk management for new business.
  • Transition management and organizational realignment.
Keywords
Strategy, Leadership, Transformation, COVID-19
Settings
South-Eastern Asia, Singapore
Zuellig Pharma, Healthcare, Pharmaceuticals
2014 – 2020
Type
Field Research
Copyright
© 2020
Available Languages
English
Related material
Teaching note
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]

Contact

Research Information & Knowledge Hub for additional information on IMD publications

This case study is part of a series
  • Zuellig Pharma (A): A case for transformation
  • Zuellig Pharma (B): Putting transformation to the test
  • Zuellig Pharma (C): Taking the next leap
This case study is part of a series
  • Zuellig Pharma (A): A case for transformation
  • Zuellig Pharma (B): Putting transformation to the test
  • Zuellig Pharma (C): Taking the next leap
Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics
Zuellig Pharma (B): Putting transformation to the test
By Katharina Lange Tawfik Jelassi and Pallivathukkal Cherian Abraham
Case reference: IMD-7-2241 ©2020
Summary
Case (B) is set in January 2020 when CEO John Davison decided to step down as CEO by end of June 2020. It describes the specific actions of Zuellig...
Reference IMD-7-2241
Copyright ©2020
Copyright owner IMD Copyright
Organization Zuellig Pharma
Industry Healthcare, Pharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications